|
|
Article: Verona Pharma Signs Deal to Start Pre-clinical Studies on Ground Breaking Hay Fever Drug.
- Article from:
- PR Newswire
- Article date:
- June 4, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LONDON, June 4 /PRNewswire-FirstCall/ -- The life-sciences company Verona Pharma plc., has signed a contract with LAB Research Inc. of Hungary to start formal safety evaluation studies of its lead compound, RPL554, a novel long-acting bronchodilator/anti- inflammatory molecule.
RPL554 is being developed for the treatment of hay fever and asthma, which are among the most prevalent respiratory diseases in the industrialised world.
The market for the treatment of these diseases is estimated to be some US$20 billion. Many of the available treatments have either unwanted side effects or limited effectiveness, creating a medical need in this market that ...